Prominent Brazilian University Embarks on Phase 2 Ivermectin Clinical Trial

Prominent Brazilian University Embarks on Phase 2 Ivermectin Clinical Trial

The Federal University of Sao Carlos, (UFSCar) a public research university located in Sao Carlos, in the state of Sao Paulo Brazil was established in 1968 and supports the education of over 15,000 undergraduates and about 4,700 graduate students. Ranked among the top 10 universities in Brazil, the Brazilian Ministry of Education assigned UFSCar a maximum teaching quality score. The university just initiated a Phase 2 clinical trial investigating Ivermectin as a therapeutic treatment against SARS-CoV-2.

The Context

Brazil has emerged a major hotbed of COVID-19 activity only surpassed by the United States. With just over 1.5 million reported cases and 62,304 deaths, COVDI-19 causes patient suffering and death combined with overburdened hospitals. Therapeutic options are desperately needed. The current approved drugs, such as Remdesivir, are quite limited in that it requires hospitalization and intravenous administration and only condenses the amount of time hospitalized a few a few days. Developing new drugs from scratch is an incredibly expensive, long term proposition that given the imminent nature of the crisis, isn’t a great option. Aside from Favipiravir (Russia, China a...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee